Traders bought shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading on Friday after an insider sold shares in the company. $201.22 million flowed into the stock on the tick-up and $77.07 million flowed out of the stock on the tick-down, for a money net flow of $124.15 million into the stock. Of all equities tracked, Gilead Sciences had the 9th highest net in-flow for the day. Gilead Sciences traded down ($0.19) for the day and closed at $80.98Specifically, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total value of $3,681,000.00. Following the completion of the sale, the insider now owns 3,046,766 shares of the company’s stock, valued at $224,302,912.92. The disclosure for this sale can be found here. Insiders sold a total of 591,666 shares of company stock valued at $44,466,567 over the last quarter. 1.30% of the stock is owned by corporate insiders.
GILD has been the subject of several research analyst reports. Mizuho reiterated a “buy” rating on shares of Gilead Sciences in a report on Friday, September 29th. Jefferies Group restated a “hold” rating and set a $93.00 price target on shares of Gilead Sciences in a research note on Wednesday, October 4th. Bank of America cut their price target on Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating for the company in a research note on Wednesday, October 4th. Oppenheimer began coverage on Gilead Sciences in a research note on Thursday, October 5th. They set a “market perform” rating for the company. Finally, CIBC began coverage on Gilead Sciences in a research note on Thursday, October 5th. They set a “market perform” rating for the company. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $85.53.
The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The stock has a market capitalization of $105,750.00, a price-to-earnings ratio of 9.21, a P/E/G ratio of -1.77 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same period in the previous year, the firm earned $2.75 EPS. The firm’s revenue was down 13.2% compared to the same quarter last year. research analysts forecast that Gilead Sciences, Inc. will post 8.48 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were issued a $0.52 dividend. The ex-dividend date was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.57%. Gilead Sciences’s dividend payout ratio is presently 23.66%.
A number of hedge funds and other institutional investors have recently bought and sold shares of GILD. Welch Investments LLC purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $108,000. Wealthcare Advisory Partners LLC purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $133,000. Horan Capital Advisors LLC. purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $144,000. Hanson & Doremus Investment Management raised its holdings in shares of Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $147,000. 75.95% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/19/traders-buy-shares-of-gilead-sciences-gild-on-weakness-on-insider-selling.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.